Ricerca
Didattica
Soluzioni
Accedi
IT
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Department of Molecular and Medical Pharmacology
This submission is to adjust the dimension of the profile photo.
Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 07, 2017 | Pubmed ID: 27879367
Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer.
Endocrine-related cancer 01, 2019 | Pubmed ID: 30400004
David Geffen School of Medicine, University of California, Los Angeles
University of California Los Angeles
Moe Ishihara*,1,
Junhui Hu*,1,
Xiaoyu Zhang2,
YongHyeon Choi3,
Anthony Wong4,
Celine Cano-Ruiz5,
Rongwei Zhao6,
Ping Tan7,
Jonathan L. Tso1,
Lily Wu1,8
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles,
2Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles,
3Department of Bioengineering, Hanyang University,
4Department of Ecology and Evolutionary Biology, University of California, Los Angeles,
5Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles,
6School of Life Sciences, Beijing Normal University,
7Department of Urology, West China Hospital, Sichuan University,
8Department of Urology, David Geffen School of Medicine, University of California, Los Angeles
Allison C. Sharrow1,
Moe Ishihara1,
Junhui Hu1,
Il Hyun Kim1,
Lily Wu1
1Molecular and Medical Pharmacology, University of California Los Angeles
Riservatezza
Condizioni di utilizzo
Politiche
Contattaci
SUGGERISCI JOVE ALLA BIBLIOTECA
Newsletter di JoVE
JoVE Journal
Raccolta di metodi
JoVE Encyclopedia of Experiments
Archivio
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Sportello unico per docenti
Autori
Personale delle biblioteche
Accesso
CHI SIAMO
Copyright © 2024 MyJoVE Corporation. Tutti i diritti riservati